What's New on Pep IQ

The reconstitution calculator now works the way it should. You choose how much bacteriostatic water to add to the vial; it works out exactly how many units to draw on a U-100 insulin syringe for your dose, and how many doses the vial gives you. It also catches the dangerous mistakes — a dose larger than the whole vial, more water than the vial can physically hold, or a draw too small to measure accurately. Free to use on the Prep Guide. Information only — not medical advice. Open the calculator →

Every protocol has been rebuilt from the ground up. The old prescriptive annual calendars are gone, replaced with honest, information-only references. Each one now shows the compounds in the stack (a snapshot card plus a link to the full entry), where the protocol actually originated, its evidence grade, and an estimate of real-world human exposure — alongside a plain statement of what's popular versus what's actually been trialled. No schedules to follow and no dosing prescriptions: just what the record shows. Browse protocols →

A new section covering the Russian peptide bioregulators — the short-peptide family associated with Prof. Vladimir Khavinson's work (Epitalon, Thymalin and others). Six compound entries plus their protocol references, each documenting the original Russian clinical literature, what has and hasn't been replicated independently, and current regulatory status. Written in the same conditional voice as the rest of the platform: documented, not hyped. The hub is free to browse.

Two new Frontier entries. SNAP-8 — a topical acetyl-octapeptide studied for softening expression lines. Cagrilintide — a long-acting amylin analogue in late-stage obesity trials and increasingly seen on the grey market. MariTide (maridebart cafraglutide) is logged as a pipeline "Coming Soon": trial-stage only, not yet available — the full entry opens when there's something solid to document.

Status strips on the affected compounds have been updated. In April 2026 the FDA removed BPC-157, TB-500, Epitalon and several others from the restricted Category 2 bulk-substances list, and a Pharmacy Compounding Advisory Committee review is scheduled for 23–24 July 2026. The key point, stated plainly on the cards: removal from the restricted list is not approval — these remain unlicensed in the UK (MHRA), and the US position is still evolving. Framed conditionally rather than overstated.

The first weekly compound drop is live. Larazotide (AT-1001) — the most-studied zonulin antagonist in the peptide space, originally developed for celiac disease and now investigated in MIS-C, IBS, and broader gut-barrier dysfunction. Excellent safety record across thousands of trial subjects. Lives in Part One (Healing & Recovery). The "Just In" tag stays on the card for the week. Read the entry →

Pep IQ's rolling peptide news digest goes live Monday 25 May. Every fortnight: regulatory updates, late-stage trial readouts, pipeline movement, community protocol shifts, and safety signals — bullet-pointed, sourced, conditional voice where evidence is still developing. Pinned to the top of /blog, with the archive tracking every past digest.

Experimental section restructured. Dose guidance removed from all frontier-compound protocols. Compounds documented with mechanism and research context only — no dose or administration guidance where human evidence is limited.

Full compound entry added. Phase 3 trial data showing 24% body weight reduction documented. Mechanism, trial context and research summary included. Experimental classification — Phase 3 compound, not yet licensed.

Partner programme updated. Now open to PTs, clinics and health businesses only — by application. 20% commission on referred subscriptions. No open affiliate signup.

Compound entry added for Amycretin. Superior Phase 2 results vs semaglutide alone documented. Mechanism and early trial data included. Experimental classification.

All clinic-tier protocols updated with physician supervision notices. HGH, TRT, Female Hormonal and Clinic Injury protocols framing clarified. Information and blood work guidance retained.

All 20 protocol references reviewed and updated — mechanism, evidence and dose conventions checked against the current research.